Oncothyreon

2601 4th Ave Ste 500 , Seattle, WA 98121

Public
Healthcare & Pharmaceuticals - Biotechnology
around $2.5 - 5M
around 20 - 50
(206) 801-2100
(206) 801-2101
bd@oncothyreon.com


Oncothyreon Inc. (Oncothyreon) is a clinical-stage biopharmaceutical company focused primarily on the development of therapeutic products for the treatment of cancer. The Company?s cancer vaccines are designed to stimulate the immune system to attack cancer cells, while its small molecule compounds are designed to inhibit the activity of specific cancer-related proteins. Its lead product candidate, Stimuvax, is a cancer vaccine being evaluated in two Phase III clinical trials for the treatment of non-small cell lung cancer (NSCLC). It has granted worldwide license to Merck KGaA of Darmstadt, Germany (Merck KGaA), for the development, manufacture and commercialization of Stimuvax. Merck KGaA has completed enrollment of 1514 patients in the Phase III START trial of Stimuvax in NSCLC.... (Source: SEC reports)


Brand Quality - 1/2
Do you believe in Oncothyreon's mission?


Result Not Found.

8 Contacts at this company
Ken Brasel
Staff Scientist
Peggy; Dreyfus
Executive Assistant
Kim Fuller
Director, Case Management Operations
Michael A. Insko
Scientist
Peggy Dreyfus
Executive Assistant
Kevin Klucher
Senior Director, Biology
Robert Kirkman
President and CEO
Eric Charles
Quality Assurance

No company news available.
Get Started Today : Sign up in 20 seconds
Search with 20+ criteria.
Export results in seconds.
Bad emails?
No worry, we give two extras for every bad email.